Drug Approval | January 12, 2023
USFDA inspects Piramal Pharma Lexington facility
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
The company is one of the most profitable companies manufacturing speciality chemicals in India
Allam was serving recently as the CEO at Public Investment Fund
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
Subscribe To Our Newsletter & Stay Updated
